AKTS

Aktis Oncology

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

Singapore

Next Earnings Date

06/29/26

Business Summary

Currenc Group operates in application software, likely monetizing through transaction-based fees, subscription software, or financial technology infrastructure services. The business model depends on scaling digital platforms where incremental users should theoretically expand margins, yet current operating data suggests scale inefficiency. A durable moat in this segment would typically come from network effects, embedded integrations, or switching costs within enterprise systems. Whether that moat exists in practice depends entirely on its ability to stabilize margins and convert revenue into sustainable operating cash flow.

VALUATION

P/E

-

Market Cap ($M USD)

$934

Forward P/E

-

PEG

-

PRICE TO SALES

137

PRICE TO BOOK

-

EV / EBITDA

-9.9

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

-

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.21

Next Year EPS Growth Estimate

-$1.66

Next Year Revenue Growth Estimate

122.20%

Return on Equity (ROE)

43.60%

Operating Margin

-1149.50%

Debt-to-Equity

-

Piotroski F-Score

-

Altman Z-Score

0.5

Return on Invested Capital (ROIC)

47.40%%

Current Ratio

7.4

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At a $271M market cap with no P/E, no Forward P/E, and an Altman Z-Score of 0.5, this is not a growth stock — it is a balance sheet stress story trading on hope. The absence of earnings, EPS at -8.5, and an operating margin of -11900.80% signal a company that is not simply unprofitable but structurally broken at the operating level. A Price/Sales ratio of 6.8 combined with a Price/Book above 500 suggests extreme multiple distortion relative to its underlying equity base. The market is not mispricing safety here — it is pricing speculation — and the 0.5 Altman Z-Score puts the company firmly in financial distress territory.

AI Exposure / Tech Reliance

As a Software - Application company in the Technology sector, Currenc Group operates in a segment that is inherently exposed to AI-driven automation and workflow digitization. However, the ability to capitalize on AI requires capital discipline and scalable margins, neither of which are evident given the -11900.80% operating margin. Without operating leverage, technological positioning alone will not translate into durable competitive advantage.

The Bull Case

A deep value or GARP investor looking for asymmetric upside could argue that a Piotroski F-Score of 7 indicates improving internal financial metrics despite headline losses. Return on Equity of 13.50% suggests that, at least on reported equity, the company is generating positive shareholder returns, which is unusual alongside deeply negative EPS. The current ratio of 1.2 indicates short-term liquidity is not collapsing, and a TTM Yield of 50.3 could attract capital seeking cash-based return metrics. With a Mean Consensus Target Price of 3 and a Consensus Rating of 2.70%, there is at least moderate analyst neutrality rather than outright capitulation, leaving room for rerating if operational efficiency improves.

The Bear Case

The bear case is overwhelming. An operating margin of -11900.80% and ROIC of -213.10% reflect catastrophic capital allocation and an inability to convert invested capital into profit. Debt/Equity at -31.30% combined with a Price/Book over 500 indicates a severely distorted equity structure, likely driven by accumulated losses. Sales Growth Next Year projected at -$0.25 offers no growth catalyst, EPS Next Year at -$0.85 confirms continued losses, and the Altman Z-Score of 0.5 signals elevated financial distress risk. This is not a temporary earnings dip — it is a structurally impaired operating model trading at 6.8 times sales despite negative returns.

Market Sentiment & Smart Money

Short Interest %

3.80%

Analyst Consensus

1

Average Analyst Price Target

$32.50

Institutional Ownership %

42.00%

1-Year Beta

2.18

Insider Buying % (6 Mo)

12.30%%

Distance to 52-Week High

57.90%%

Distance to 52-Week Low

114.70%%